(Q36103159)

12 August 2017

1 reference

title

Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients (English)

1 reference

12 August 2017

Heidi H Kong

1

1 reference

PubMed ID

15842613

12 August 2017

Sarah A Myers

series ordinal

2

1 reference

12 August 2017

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

18

1 reference

12 August 2017

1

1 reference

12 August 2017

58-66

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Cutaneous disease and drug reactions in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Sweet's syndrome following abacavir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Zidovudine-induced leukocytoclastic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Hypersensitivity of zidovudine: report of a case of anaphylaxis and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Peripheral oedema and high arterial blood flow as a complication of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Didanosine as probable cause of Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Cutaneous vasculitis associated with didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Incidence of rash and discontinuation of nevirapine using two different escalating initial doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Efavirenz-induced skin eruption and successful desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Efavirenz-induced leukocytoclastic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Viral dynamics in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

21 January 2018

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Indinavir-associated maculopapular eruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Xanthomas and hyperlipidemia in a human immunodeficiency virus-infected child receivng highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Protease inhibitor-associated angiolipomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Risk factors for lipodystrophy in the CISAI cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Subcutaneous granulomatous lesions related to ritonavir therapy in a HIV infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Cutaneous injection site reactions to long-term therapy with enfuvirtide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Immune restoration disease after antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Treatment of recurring cutaneous drug reactions in patients with human immunodeficiency virus 1 infection: a series of 3 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Alopecia Associated with Indinavir Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

Anaphylaxis after rechallenge with abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.05004.X

10.1111/J.1529-8019.2005.05004.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15842613